Plamotamab for Blood Cancers

Recruiting in Palo Alto (17 mi)

+31 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Xencor, Inc.

No Placebo Group

Trial Summary

What is the purpose of this trial?

The purpose of this study is to determine the safety and tolerability of intravenous (IV) and subcutaneous (SC) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) and/or recommended dose (RD).

Eligibility Criteria

This trial is for patients with certain blood cancers like lymphoma and leukemia who have tried all standard treatments without success. They should be in a stable condition (ECOG 0-2), not planning stem cell transplants, and must agree to effective contraception. Excluded are those with severe recent illness, heart or lung issues, high toxicity from past treatments, CNS lymphoma, active infections or autoimmune diseases.

Inclusion Criteria

I can take care of myself and am up and about more than half of the day.

Fertile patients must agree to use highly effective contraception during and for 5 months (male patients) and 8 months (female patients) after last dose of XmAb13676

I am willing and able to participate in the whole study.

See 8 more

Exclusion Criteria

I haven't had chemotherapy, radiotherapy, or immunotherapy in the last 4 weeks.

I have had brain lymphoma or cancer affecting my nervous system.

I have been diagnosed with multiple myeloma, plasma cell leukemia, or B cell acute lymphoblastic leukemia.

See 19 more

Treatment Details

Interventions

XmAb13676 (Monoclonal Antibodies)

Trial OverviewThe study tests the safety of XmAb13676 (Plamotamab) given through IV or SC injections in different doses to find the highest dose patients can tolerate without serious side effects. It's aimed at people whose cancer hasn't responded well to other therapies including anti-CD20 antibody treatment.

Participant Groups

6Treatment groups

Experimental Treatment

Group I: Non-CLL B Cell Malignancies (Group NHL) Part D / ExpansionExperimental Treatment1 Intervention

XmAb13676 administered SC up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion

Group II: Non-CLL B Cell Malignancies (Group NHL) Part C / ExpansionExperimental Treatment1 Intervention

XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion

Group III: Non-CLL B Cell Malignancies (Group NHL) Part BExperimental Treatment1 Intervention

XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion

Group IV: Non-CLL B Cell Malignancies (Group NHL) Part AExperimental Treatment1 Intervention

XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion

Group V: CLL/SLL (Group CLL) Part BExperimental Treatment1 Intervention